SecBot SecBot
8-K ·Filed Nov 12, 2026

INKT

MiNK Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed4d 16h ago SEC0001193125-26-457244
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor U.S. site activation and dosing in the randomized ARDS trial before year-end, and the FDA meeting on the adaptive Phase 2b/3 design. The named-patient revenue stream is small and variable but provides proof of commercial infrastructure.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

INKT drug pipeline →

agenT-797

● Neutral Named in this 8-K
Impact
Phase
Phase 2
Time to market
agenT-797 is not approved in any market. The most advanced program is the randomized Phase 2 ARDS trial (C-1300-02), with data expected in 2H2027. Even with positive data, additional trials and regulatory review would be needed before any potential approval, likely several years away.
Next catalyst
None dated

What to watchThe next hard catalyst is the U.S. dosing initiation in the randomized Phase 2 ARDS trial (C-1300-02), expected before year-end 2026, with topline data not expected until 2H2027. In the nearer term, watch for any updates on the ARPA-H BoSS program funding allocation and enrollment progress in the ongoing Phase 2 colorectal cancer trial. The company's $7.5M cash position and $1.3M quarterly operating burn suggest a financing event may be needed within 2-3 quarters to fund the ARDS trial through readout.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$9.53
T+0 close · Nov 12, 2026 · via day close
Latest settled
−1.99%
T+1 · $9.34
Vs SPY
−1.63%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $9.53entry
  2. T+1 · 4d ago −1.99%α −1.63% · $9.34
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MiNK Therapeutics reported Q3 2026 net loss of $2.6M ($0.50/share), a 23% year-over-year improvement from $2.9M ($0.65/share), and recognized its first pre-commercial product revenue of $0.2M from the named-patient access program for agenT-797. The randomized Phase 2 ARDS trial is advancing with U.S. dosing expected before year-end, and the company was selected for the ARPA-H BoSS program (up to $87M in program-wide funding). Cash burn was the lowest of 2026 at $1.3M in operating cash use.

Key Financial Metrics

EPS
−$0.50
est −$0.58 · +13.8%
Revenue
$200.0K
est $0.00
Rating
beat

Key Facts

  • Q3 2026 net loss $2.6M vs $2.9M in prior-year quarter, a 23% improvement in net loss per share
  • First pre-commercial product revenue of $0.2M from agenT-797 named-patient access program
  • Cash and cash equivalents $7.5M at Sept 30, 2026, down from $8.8M at June 30, 2026
  • Cash used in operations $1.3M, the lowest quarterly operating cash use of 2026
  • G&A expense declined 44% to $1.0M; R&D expense increased to $1.8M from $1.1M
  • Randomized Phase 2 ARDS trial (C-1300-02) enrolling; U.S. dosing expected before year-end 2026
  • Selected for ARPA-H BoSS program with up to $87M in program-wide funding over four years
  • Net loss per share $0.50 vs consensus estimate of $0.58 (beat by 13.8%)

Financial Impact

Net loss improved 23% YoY to $2.6M; first product revenue of $0.2M; cash burn reduced to $1.3M in operations

net losscash burnproduct revenue

Risk Factors

  • Cash runway limited to $7.5M; company is pursuing equity/debt financing to fund through ARDS readout in 2H2027
  • Named-patient revenue is variable and depends on case-by-case regulatory authorizations
  • ARDS trial data not expected until 2H2027; interim observations from small patient numbers may not predict outcomes

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-457244
Document: inkt-20261112.htm0001193125-26-457244
Document: 0001193125-26-457244-index-headers.html0001193125-26-457244
Document: 0001193125-26-457244-index.html0001193125-26-457244
Document: 0001193125-26-457244.txt0001193125-26-457244
8-K Data (Synthetic)0001193125-26-457244

Track record

21 reports on INKT

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Viewing Entry $9.53 Now $9.35 −1.89% settles Dec 11
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
  3. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
  4. Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
  5. Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
  6. Aug 13, 202613w ago 8-K Mixed 6/10 No price data
  7. Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
  8. Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
  9. May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
  10. May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 7h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026